Brief: Trevi Therapeutics Announces First Quarter 2023 Financial Results And Provides Business Update

Trevi Therapeutics

11/05/2023 22:03

Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS ANNOUNCES FIRST QUARTER 2023 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * INITIATING THREE CLINICAL STUDIES IN CHRONIC COUGH
INDICATIONS
LATER THIS YEAR
    * TREVI - RECEIVED NOTICE OF ALLOWANCE FOR KEY U.S. PATENT
FOR USE
OF ORAL NALBUPHINE ER FOR TREATMENT OF CHRONIC COUGH IN
IDIOPATHIC PULMONARY FIBROSIS
    * QTRLY LOSS PER SHARE $0.06
    * Q1 EARNINGS PER SHARE VIEW $-0.07 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nPn8gq8Lda 
Further company coverage:  TRVI.O